HPV Vaccination's Effectiveness in Preventing Cancer Confirmed

HPV vaccination reduced cervical precancer rates by 79.5% in the 20-24 age group. CIN2+ cases fell by 11% each year. The vaccine's effectiveness has been confirmed!

A Major Decline in Precancerous Cervical Lesions

According to new data from the United States Centers for Disease Control and Prevention (CDC), widespread use of the human papillomavirus (HPV) vaccine has led to a decline among women aged 20-24 in cervical precancer incidence of approximately 80%.

HPV vaccination was first recommended in 2006 to prevent HPV-related cancers and diseases. The CDC began tracking cervical precancer incidence in 2008 to monitor its impact. According to a new study led by Dr. Julia W. Gargano and colleagues at the CDC's National Center for Immunization and Respiratory Diseases, the vaccine's impact on preventing cervical cancer is becoming increasingly clear.

Study Findings

On February 27, 2025, Morbidity and Mortality Weekly Report published this study, which examined data from the HPV Vaccine Impact Monitoring Project (HPV-IMPACT) to analyze changes in rates of cervical intraepithelial neoplasia 2+ (CIN2+; CIN 2-3 and carcinoma in situ) and CIN3+ (CIN 3 and carcinoma in situ) over time.

Data from women aged 20-64 during 2008-2022 included 39977 CIN2+ cases, of which 13027 (32.6%) were CIN3+. Overall, women aged 20-24 experienced an 11% annual reduction in CIN2+ cases , with a total decline of 79.5% between 2008-2022.

Among women aged 25-29, CIN2+ rates rose by 3.1% annually during 2008-2016 but then fell by 4.3% annually during 2016-2022. Women in their 30s also experienced an increase in cervical precancer incidence during 2008-2016, followed by a downward trend after 2016. Among women aged 40-64, CIN2+ rates from 2008 to 2022 showed a marked increase .

Public Health Implications

The researchers noted several limitations. Using insurance claims and survey data to identify women undergoing cervical screening may not fully reflect actual precancer rates. Changes in screening and management guidelines over time may also affect the data. Nevertheless, these findings support the sustained impact of HPV vaccination in reducing cervical precancers.

Conclusions and Commentary

These studies, which show the early effects of HPV vaccination, provide clearer information about its long-term impact.

That HPV vaccination prevents cancer and saves lives is now an established fact. Our foremost priorities are to include HPV vaccination in the national immunization program, ensure all eligible adolescents, regardless of sex, are vaccinated before HPV exposure, and address vaccine hesitancy.

False anti-vaccine narratives spreading rapidly on social media also undermine trust in vaccines, including HPV vaccination. Unfounded claims that HPV vaccination causes infertility, autoimmune diseases, or early sexual activity misinform the public. Healthcare professionals must therefore respond clearly and firmly with scientific evidence.

In conclusion, this study demonstrates that HPV vaccination is effective in preventing cervical precancers. Recommending vaccination early and at the appropriate time remains a crucial responsibility for physicians.